McKesson Corporation vs Visa Inc — how do they compare? McKesson Corporation trades at $824.42 (market cap $97.35B), while Visa Inc trades at $357.58 (market cap $685.71B). The key difference: Visa Inc is far larger — about 7× McKesson Corporation's market cap, and Visa Inc pays the higher dividend (0.74%). Which is the better fit depends on your goals.
| MCK | V | |
|---|---|---|
Market Cap | $97.35B | $685.71B |
Sector | Health | Financials |
52-Week High | $995.69 | $365.14 |
52-Week Low | $659.01 | $295.52 |
Enterprise Value | $101.98B | $696.30B |
Dividend Yield | 0.39% | 0.74% |
Volume | — | 10,431,336 |
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
Visa (V) trades at $358.00, down 0.16% on the day, with a bullish technical outlook supported by moving averages and a consensus price target of $396.70. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $3.31 surpassing expectations. Revenue growth remains robust, rising to $40.0B in 2025, while maintaining high net income margins above 50%. Recent news highlights Visa's expansion into AI-driven commerce and stablecoin partnerships, positioning it for future growth in digital payments.
The stock offers solid upside potential based on analyst targets, but faces risks from competitive fintech disruption and regulatory pressures. High valuation multiples like a P/E of 31.44 require sustained earnings growth. Institutional ownership trends show continued interest, with recent filings indicating increased positions by firms like Banque de Luxembourg. Overall, Visa's strong fundamentals and strategic initiatives support a positive long-term outlook, though investors should monitor execution risks.
Trailing returns across standard periods
Latest headlines on both assets
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →